Connect with us

Biotech

Several companies participate at the European Biotech Week

The experts taking part in the European Biotech Week will address the issue of safety and regulation in the biotech field: from laboratory handling to clinical trials, for the development of vaccines against Sars-Cov-2. They will also discuss how the new discoveries of neuroscience can shed new light on the many different aspects that affect the way of learning

Published

on

Inail participates for the second year at the European Biotech Week (Ebw), a week of events and meetings around the world to illustrate biotechnology to a wide and diverse audience, coordinated and promoted nationally by Assobiotec-Federchimica. 

The event, which focuses on the key role that biotech plays in improving the quality of life, was launched in Canada in 2003 and arrived in Europe in 2013. Since 2016, the event has been organized in different continents, creating a real “Global Biotech Week”, demonstrating how biotechnology is a boundless resource, able to offer solutions to the great challenges facing society worldwide.

If you want to find more details about the European Biotech Week and what are the main subjects to be discussed by the companies taking part in the event, download for free the Born2Invest mobile app. Our companion app brings you the latest financial headlines in the world and the most important discoveries in the biotech sector. 

The “emerging” themes of the Biotech sector

The event taking place on October 1st and 2nd is organized by the Department of Technological Innovations and Safety of Plants, Products, and Human Settlements. The aim of the event is to raise awareness among teachers and students of Higher Education Institutes on the issues of the biotech sector, considered “emerging” and therefore requiring more attention, individual responsibility, and awareness on opportunities and new risks. 

Epigenomics and correct lifestyles; the new homic sciences and artificial intelligence

Companies taking part at the event will talk about epigenetics and correct lifestyles, in order to raise awareness of the importance of adopting correct behaviors and lifestyles promoting awareness of their choices, a topic of particular importance in this time of pandemic.

SEE ALSO  Deciphering the simple moving average

Another topic discussed will be that of circadian regulation of genes that, if altered, can have a negative impact on different physiological functions and determine a predisposition to developing cancer, cardiovascular and metabolic diseases including obesity and diabetes. Particularly interesting is the topic of new biotech techniques in relation to safety in the food industry. Finally, it will be discussed about artificial intelligence as a useful tool for the interpretation of the large amount of data produced by biotechnological research.

Safety and biotech: from the laboratory to clinical trials, at the time of the pandemic

The Italian biotech world is the protagonist of an extraordinary development, due to the undisputed excellence of academic and industrial research. Biotech applications in the biomedical field currently represent the sector in which biotechnology has made the most significant contribution, both in terms of therapeutic products and research and development. 

The experts will also address the issue of safety and regulation in the biotech field: from laboratory handling to clinical trials, for the development of vaccines against Sars-Cov-2. In conclusion, it will be discussed how the new discoveries of neuroscience can shed new light on the many different aspects that affect the way of learning, an important issue for safety training activities. 

The event organized on the occasion of the scientific divulgation event European Biotech Week (Ebw) at the DCOD Inail headquarters in Rome will also be live-streamed.

__

(Featured image by FotoshopTofs via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PuntoSicuro, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Anthony Donaghue writes about science and technology. Keeping abreast of the latest tech developments in various sectors, he has a keen interest on startups, especially inside and outside of Silicon Valley. From time to time, he also covers agritech and biotech, as well as consumer electronics, IT, AI, and fintech, among others. He has also written about IPOs, cannabis, and investing.